Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 2019-2025

Pulmonary Angiotensin-converting Enzyme (ACE) Binding and Inhibition in Humans
A Positron Emission Tomography Study

FENG QING, TIMOTHY J. McCARTHY, JOANNE MARKHAM, and DANIEL P. SCHUSTER

Departments of Medicine and Radiology, Washington University School of Medicine, St. Louis, Missouri

Angiotensin-converting enzyme (ACE) inhibition attenuates pulmonary hypertension and delays the development of pulmonary vascular remodeling in animal models. Thus, ACE inhibition might be a useful treatment for primary pulmonary hypertension (PPH). To determine the dose of ACE inhibitor required to specifically block pulmonary ACE in humans, we measured the combined forward rate constant (CFRC) for [¹⁸F]-fluorocaptopril, which is proportional to the mass of ACE in the lung, using positron emission tomography (PET). In five normal subjects, CFRC was measured twice, 1 wk apart, to assess measurement reproducibility. The CFRC was 0.151 ± 0.067 for the first measurement and 0.140 ± 0.060 for the second measurement (p = not significant [NS]). In five normals, CFRC decreased on average 84%, from 0.177 ± 0.053/s to 0.028 ± 0.017/s (p < 0.05), after 1 wk ingestion of 5 mg enalapril orally once a day (the scans were performed 24 h after the last medication). Similarly, in five patients with PPH, CFRC decreased on average 76%, from 0.052 ± 0.020/s to 0.012 ± 0.003 (p < 0.01), after 1 wk enalapril, despite much lower baseline values. We conclude that the total mass of pulmonary ACE appears to be significantly reduced in PPH and that only low doses of ACE inhibitors may be needed to block the effects of ACE on vascular remodeling in PPH.

This article has been cited by other articles:

				Y. Chandrashekhar and J. Narula Exposing ACE up the Sleeve... J. Nucl. Med., February 1, 2007; 48(2): 173 - 174. [Full Text] [PDF]

				E. Gurbanov and X. Shiliang The key role of apoptosis in the pathogenesis and treatment of pulmonary hypertension. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 499 - 507. [Abstract] [Full Text] [PDF]

				M. J. TOBIN Chronic Obstructive Pulmonary Disease, Pollution, Pulmonary Vascular Disease, Transplantation, Pleural Disease, and Lung Cancer in AJRCCM 2000 Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1789 - 1804. [Full Text] [PDF]

				S. Kanno, Y.-J. L. Wu, P. C. Lee, T. R. Billiar, and C. Ho Angiotensin-Converting Enzyme Inhibitor Preserves p21 and Endothelial Nitric Oxide Synthase Expression in Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats Circulation, August 21, 2001; 104(8): 945 - 950. [Abstract] [Full Text] [PDF]

				L. A. Ortiz, H. C. Champion, J. A. Lasky, F. Gambelli, E. Gozal, G. W. Hoyle, M. B. Beasley, A. L. Hyman, M. Friedman, and P. J. Kadowitz Enalapril protects mice from pulmonary hypertension by inhibiting TNF-mediated activation of NF-kappa B and AP-1 Am J Physiol Lung Cell Mol Physiol, June 1, 2002; 282(6): L1209 - L1221. [Abstract] [Full Text] [PDF]